Jianhui Wu

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research

Ming Liu, Chengzhi Zhou, C. Su, 2022, Frontiers in Oncology.

Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer

Ming Liu, Chengzhi Zhou, Xiaohong Xie, 2022, Respiratory Research.

Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study

Ming Liu, Wen Lin, Jiexia Zhang, 2022, Frontiers in immunology.

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI

Ming Liu, Chengzhi Zhou, Xiaohong Xie, 2021, Frontiers in Oncology.

Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer

Yong Song, Ming Liu, Suyang Li, 2021, Frontiers in Oncology.

Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer

Xiaohui Xie, Ming Liu, Chengzhi Zhou, 2021, Frontiers in Oncology.

A Risk-Scoring Model for Severe Checkpoint Inhibitor-Related Pneumonitis: A Case–Control Study

Ming Liu, Chengzhi Zhou, Xiaohong Xie, 2023, Clinical Drug Investigation.

双免疫联合治疗在晚期非小细胞肺癌中的一线应用

Chengzhi Zhou, Liqiang Wang, Yilin Yang, 2022, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report

Xiaohui Xie, Ming Liu, Chengzhi Zhou, 2023, Human vaccines & immunotherapeutics.